⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15699050 | 0.84 | KCNH2 (0.41) | — | |
| SCHEMBL318096 | 0.82 | KCNH2 (0.57) | — | |
| SCHEMBL9878020 | 0.80 | SCN9A (0.53) | — | |
| SCHEMBL18655885 | 0.78 | — | — | |
| SCHEMBL8329395 | 0.77 | XIAP (0.47) | — | |
| SCHEMBL3224012 | 0.76 | XIAP (0.54) | — | |
| SCHEMBL1099019 | 0.76 | CACNA1C (0.51) | — | |
| SCHEMBL3151894 | 0.75 | NCF1 (0.48) | — | |
| SCHEMBL3249750 | 0.74 | XIAP (0.41) | — | |
| SCHEMBL13403442 | 0.74 | XIAP (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022166920-A1 | PYRROLOPYRIDAZINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州中美华东制药有限公司 | 2022-08-11 | — | — | WO | disclosed |
| WO-2020216350-A1 | QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | 中国人民解放军军事科学院军事医学研究院 | 2020-10-29 | — | — | WO | disclosed |
| EP-2488513-B1 | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases | AC IMMUNE SA (CH) | 2017-12-27 | — | — | EP | disclosed |
| US-20160368929-A1 | MELAMPOMAGNOLIDE B DERIVATIVES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160368928-A1 | MELAMPOMAGNOLIDE B DERIVATIVES | BIOVENTURES, LLC | 2016-12-22 | — | — | US | disclosed |
| US-9487536-B2 | Melampomagnolide B derivatives | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RES INC (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RES INC (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RES INC (US) | 2016-10-27 | — | — | US | disclosed |
| US-9469650-B2 | Melampomagnolide B derivatives | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2016-10-18 | — | — | US | disclosed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009051822-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009051822-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| CN-101072758-A | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-11-14 | — | — | CN | disclosed |
| EP-1802591-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007002441-A1 | METHODS OF USE FOR NON-ATP COMPETITIVE TYROSINE KINASE INHIBITORS TO TREAT PATHOGENIC INFECTION | EMORY UNIVERSITY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006040520-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |